Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Key Inclusion Criteria: * Individuals with pathologically documented evidence of Stage IV non-small cell lung Cancer (NSCLC) disease at the time of enrollment * Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST Version 1.1 criteria by investigator * No prior systemic treatment for metastatic NSCLC * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Adequate hematologic counts * Adequate hepatic function Key Exclusion Criteria: * Mixed SCLC and NSCLC histology * Active second malignancy * NSCLC that is eligible for definitive local therapy alone * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has had an allogenic tissue/solid organ transplant. * Has severe (≥ Grade 3) hypersensitivity to SG, pembrolizumab, carboplatin, or cisplatin, their metabolites, or formulation excipient * Has received radiation therapy to the lung * Individuals may not have received systemic anticancer treatment within the previous 6 months * Is currently participating in or has participated in a study of an investigational agent * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Known active central nervous system (CNS) metastases * History of cardiac disease * Active chronic inflammatory bowel disease * Active serious infection requiring antibiotics * Active or chronic hepatitis B infection * Positive hepatitis C antibody * Positive serum pregnancy test or women who are lactating Note: Other protocol defined Inclusion/Exclusion criteria may apply.